title: Clinical relevance of dissolution testing in quality by design.
abstract: Quality by design (QbD) has recently been introduced in pharmaceutical product development in a regulatory context and the process of implementing such concepts in the drug approval process is presently on-going. This has the potential to allow for a more flexible regulatory approach based on understanding and optimisation of how design of a product and its manufacturing process may affect product quality. Thus, adding restrictions to manufacturing beyond what can be motivated by clinical quality brings no benefits but only additional costs. This leads to a challenge for biopharmaceutical scientists to link clinical product performance to critical manufacturing attributes. In vitro dissolution testing is clearly a key tool for this purpose and the present bioequivalence guidelines and biopharmaceutical classification system (BCS) provides a platform for regulatory applications of in vitro dissolution as a marker for consistency in clinical outcomes. However, the application of these concepts might need to be further developed in the context of QbD to take advantage of the higher level of understanding that is implied and displayed in regulatory documentation utilising QbD concepts. Aspects that should be considered include identification of rate limiting steps in the absorption process that can be linked to pharmacokinetic variables and used for prediction of bioavailability variables, in vivo relevance of in vitro dissolution test conditions and performance/interpretation of specific bioavailability studies on critical formulation/process variables. This article will give some examples and suggestions how clinical relevance of dissolution testing can be achieved in the context of QbD derived from a specific case study for a BCS II compound.
authors.affiliation: Pharmaceutical & Analytical R&D, AstraZeneca, Macclesfield, Cheshire, SK10 2NA, England.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Dickinson
authors.forename: Wang Wang
authors.initials: WW
authors.lastname: Lee
authors.forename: Paul W
authors.initials: PW
authors.lastname: Stott
authors.forename: Andy I
authors.initials: AI
authors.lastname: Townsend
authors.forename: John P
authors.initials: JP
authors.lastname: Smart
authors.forename: Parviz
authors.initials: P
authors.lastname: Ghahramani
authors.forename: Tracey
authors.initials: T
authors.lastname: Hammett
authors.forename: Linda
authors.initials: L
authors.lastname: Billett
authors.forename: Sheena
authors.initials: S
authors.lastname: Behn
authors.forename: Ryan C
authors.initials: RC
authors.lastname: Gibb
authors.forename: Bertil
authors.initials: B
authors.lastname: Abrahamsson
mesh_terms: D001702:Biopharmaceutics / Q000592:standards; D002986:Clinical Trials as Topic; D015195:Drug Design; D004341:Drug Evaluation / Q000379:methods*; D015507:Drugs, Investigational / Q000737:chemistry / Q000493:pharmacokinetics / Q000592:standards; D006801:Humans; D011786:Quality Control; D018570:Risk Assessment; D012995:Solubility; D013810:Therapeutic Equivalency
chemical_list: D015507:Drugs, Investigational